Bioxodes with management changes

The biologist Dechamps brings more than 30 years of management experience in the biotech and pharmaceutical industries, notably in the areas of strategic development and marketing. In his new role, he will take on the overall management of Bioxodes and oversee its transition to a clinical development company. Marc will spearhead efforts to secure the necessary funding for Bioxodes’ clinical development work and will establish strategic partnerships with key players in the pharmaceutical sector.
 
In his new role as COO, Edmond Godfroid, an expert in Ir-CPI and its potential applications, will be responsible for defining the company’s R&D strategy and operational approach in consultation with the management team. He will also ensure the ongoing development of the new molecules in the company’s drug pipeline.
 
Dechamps has extensive experience in the pharmaceutical industry dating back more than 35 years. During his career, he has worked for corporate pharma companies including GSK & ViiVHealthcare, building his expertise in market development for new products, including infectious diseases, immunological disorders, oncology, CNS disorders and vaccines. In 2016, Marc founded and became managing director of XMF consulting, a company which supports biotech and biopharma businesses with strategic advice and management leadership. He has also served as managing director of Delphi Genetics (CDMO) and interim CEO of eTheRNA Immunotherapies (a Belgian mRNA clinical stage biotech company). Marc is currently co-academic director for the newly created advanced masters in biotech & medtech ventures at the Solvay Brussels School of Economics & Management. He is also responsible for representing BioWin – the life sciences cluster of Wallonia – on the international stage – and serves as president of the board for the Council of European BioRegions (CEBR) and the investment group Investsud Tech.